Breast Cancer

Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.

NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.

Trastuzumab botidotin more than doubled median PFS vs trastuzumab emtansine in HER2-positive advanced breast cancer in the phase 3 KL166-III-06 trial.

Camizestrant/palbociclib did not significantly improve PFS vs anastrozole/palbociclib in first-line ER+/HER2– breast cancer in the phase 3 SERENA-4 trial.

Adding atezolizumab to neoadjuvant chemotherapy did not significantly improve EFS in early TNBC, but node-positive and high-TIL subgroups showed benefit.

FDA approved camizestrant for HR+/HER2– advanced breast cancer with emerging ESR1 mutations based on data from the SERENA-6 trial.

Experts in breast cancer discussed final CAPItello-291 overall survival data and their implications for capivasertib plus fulvestrant.

Lisa Cassileth, MD, FACS, discussed her retrospective study showing that upsizing breast implants does not increase mastectomy flap necrosis risk.

Neil Iyengar, MD; Rebecca Shatsky, MD; and Carol Tweed, MD, discuss camizestrant and SERENA-6 ctDNA monitoring for ESR1-mutant HR+/HER2– breast cancer.

The European Commission has approved T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer based on DESTINY-Breast09.

ASCO’s updated breast cancer follow-up guideline replaces routine, one-size-fits-all surveillance with a 3-tier, risk-based model.

Paxalisib produced a 100% clinical benefit rate and an 83% objective response rate in patients with metastatic triple-negative breast cancer.

The regulatory submission to expand the gedatolisib label to HR+/HER2-, PIK3CA-mutant advanced breast cancer is based on positive VIKTORIA-1 trial data.

Ami Shah, MD, Megan Kruse, MD, and Ruta Rao, MD, discuss DESTINY-Breast09, -11, and -05 data on trastuzumab deruxtecan in HER2-positive breast cancer.

The phase 2 Neo-CheckRay trial findings showed that adding durvalumab to radiation and chemotherapy nearly tripled pCR rates in PD-L1–negative ER+/HER2− breast cancer.

Gedatolisib plus fulvestrant, with or without palbociclib, now holds NCCN Category 1 status for HR+/HER2– PIK3CA wild-type advanced breast cancer.

Kay Yoon-Flannery, DO, MPH, FACS, described why the lateral axillary line is her preferred incision site for single-port robotic mastectomy.

Kay Yoon-Flannery, DO, MPH, FACS, discusses da Vinci Single Port robotic mastectomy, ranging from technique and patient selection to outcomes.

Kay Yoon-Flannery, DO, MPH, FACS, explained how the da Vinci Single Port 3D visualization improves precision vs open or multiport surgery.

Explore modern metastatic breast cancer care: longer survival, smarter symptom control, caregiver support, and steps to close racial treatment gaps.

Kathryn Eckert, DO, spoke about diversifying breast imaging technology after the Hologic Brevera needle recall.

Kathryn Eckert, DO, shared how her team communicates with patients and keeps referral guidelines unchanged during the shortage.

Kathryn Eckert, DO, discussed her role of bridging surgery and radiology teams as breast biopsy needle shortages continue nationwide.

Kathryn Eckert, DO, described how her breast surgery practice and imaging partners responded on day 1 of the Hologic Brevera needle recall.

A breast surgeon and a radiologist describe the impact the breast biopsy needle shortage has had on their current clinical practice.